Athira Pharma, Inc. Stock Price, News & Analysis

Athira Pharma announced the presentation of preclinical data on the therapeutic potential of enhancing the HGF/MET neurotrophic system for treating Parkinson’s disease and diabetic neuropathy at Neuroscience 2022. Presentations include 'Small Molecule Hepatocyte Growth Factor (HGF)/MET Positive Modulators Effectively Reduce Pain-Related Behaviors in a Rat Model of Diabetic Neuropathy' and 'Fosgonimeton Protects Against Neuronal Damage and Motor Deficits in Preclinical Models of Parkinson’s Disease'. Both presentations are scheduled for Nov. 14 and Nov. 15, 2022, respectively.

Athira Pharma announced positive interim results for its LIFT-AD study on fosgonimeton (ATH-1017) in Alzheimer’s patients. An independent committee recommended continuing the trial after finding it well powered with fewer than 300 patients enrolled and a preliminary positive effect size. The company aims to complete enrollment by mid-2023 and report topline results in early 2024. Previous Phase 2 results showed a favorable safety profile and cognitive benefits. The firm is optimistic about fosgonimeton's potential in treating Alzheimer's and plans further development.

Athira Pharma (NASDAQ: ATHA) announced updates on its LIFT-AD clinical trial of fosgonimeton, focusing on its use as monotherapy for mild-to-moderate Alzheimer's disease. Following positive results from the ACT-AD trial, the company will amend LIFT-AD to compare fosgonimeton alone against placebo, without background acetylcholinesterase inhibitors. An independent interim analysis will ensure the trial's sample size is sufficient for the primary endpoint, the Global Statistical Test. Over 90% of ACT-AD participants have opted for the ongoing open-label extension study.

Athira Pharma reported Q2 2022 financial results, revealing cash reserves of $282.2 million and a net loss of $24.3 million, or $0.65 per share. The ACT-AD Phase 2 trial of fosgonimeton showed no statistical significance for its primary endpoint, yet indicated potential cognitive improvement in post hoc analysis. Clinical updates include ongoing recruitment for the LIFT-AD Phase 3 study and promising preclinical data on new HGF/MET modulators. The company highlighted a strong balance sheet, supporting its ongoing clinical development pipeline.

Athira Pharma (ATHA) presented results from its ACT-AD trial for fosgonimeton, a treatment for mild-to-moderate Alzheimer's disease, at the AAIC 2022. While the primary endpoint was not statistically significant, secondary analyses showed numerical improvements in daily living activities and cognitive measures. Notably, a significant reduction in neurofilament light chain (NfL), a biomarker of neurodegeneration, was observed in a subgroup receiving fosgonimeton monotherapy. The positive tolerability profile and ongoing LIFT-AD study offer further exploration into its therapeutic potential.

Athira Pharma (ATHA) showcased preclinical data on its lead candidate, fosgonimeton (ATH-1017), at the AAIC 2022. The active metabolite, fosgo-AM, demonstrated neuroprotective effects in neuron cultures, enhancing neuron survival and neurite growth while mitigating neurotoxic impacts. Furthermore, novel orally bioavailable small molecules were shown to reverse memory deficits in animal models, promising for Alzheimer's treatment. These developments underline Athira's commitment to advancing its innovative therapies targeting neurodegenerative disorders.

Athira Pharma (NASDAQ: ATHA) announced its participation in the Alzheimer’s Association International Conference (AAIC) 2022, taking place from July 31 to August 4, 2022. Chief Medical Officer Hans Moebius will present results from the ACT-AD Phase 2 proof-of-concept study on fosgonimeton (ATH-1017) targeting mild-to-moderate Alzheimer’s patients. The conference will include discussions on novel Alzheimer’s treatments, with Athira presenting data on its small molecule HGF/MET platform aimed at neuroprotection and cognitive improvement.

Athira Pharma (ATHA) announced topline results from its ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer’s disease. The primary endpoint of statistically significant change in ERP P300 latency was not met, suggesting diminished effect when combined with standard-of-care AChEIs. However, a subgroup analysis indicated improved ERP P300 latency and cognitive performance in patients on fosgonimeton monotherapy compared to placebo. Fosgonimeton demonstrated a favorable safety profile, and insights gained will inform the ongoing LIFT-AD study.

Athira Pharma, Inc. (NASDAQ: ATHA) has established a Scientific Advisory Board (SAB) comprising leading experts in neurology and neurodegenerative diseases. The board, chaired by Athira's Chief Medical Officer, Dr. Hans Moebius, aims to provide strategic guidance for the development of Athira's novel small molecule compounds targeting conditions like Alzheimer’s and Parkinson’s disease. SAB members include prominent researchers from esteemed institutions, enhancing Athira’s capability in advancing its pipeline for neurological treatments.